Wall Street analysts predict that Alexion Pharmaceuticals (NASDAQ:ALXN) will post sales of $980.63 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Alexion Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.00 billion and the lowest estimate coming in at $969.43 million. Alexion Pharmaceuticals posted sales of $912.00 million during the same quarter last year, which suggests a positive year over year growth rate of 7.5%. The firm is scheduled to announce its next quarterly earnings report on Thursday, July 26th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year sales of $4.01 billion for the current year, with estimates ranging from $3.93 billion to $4.25 billion. For the next year, analysts expect that the firm will post sales of $4.65 billion per share, with estimates ranging from $4.40 billion to $4.81 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The firm had revenue of $930.90 million during the quarter, compared to analyst estimates of $920.50 million. During the same quarter in the prior year, the company earned $1.38 EPS. The business’s revenue was up 7.0% compared to the same quarter last year.
Several research firms recently weighed in on ALXN. BidaskClub upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Credit Suisse Group upped their price target on Alexion Pharmaceuticals from $149.00 to $154.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 5th. ValuEngine upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 24th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Citigroup upped their price target on Alexion Pharmaceuticals from $170.00 to $173.00 and gave the stock a “buy” rating in a research note on Monday, April 30th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $158.37.
Shares of Alexion Pharmaceuticals traded up $1.76, hitting $127.57, during midday trading on Monday, MarketBeat reports. The company had a trading volume of 2,326,067 shares, compared to its average volume of 1,191,942. The company has a quick ratio of 2.86, a current ratio of 3.35 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $27.99 billion, a P/E ratio of 24.72, a PEG ratio of 1.13 and a beta of 1.11. Alexion Pharmaceuticals has a 52-week low of $102.10 and a 52-week high of $149.34.
In other Alexion Pharmaceuticals news, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction on Monday, April 30th. The shares were acquired at an average cost of $120.79 per share, for a total transaction of $1,207,900.00. Following the purchase, the director now owns 26,333 shares in the company, valued at approximately $3,180,763.07. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP John J. Orloff sold 2,115 shares of the stock in a transaction on Friday, June 8th. The shares were sold at an average price of $118.53, for a total value of $250,690.95. Following the sale, the executive vice president now owns 31,790 shares in the company, valued at $3,768,068.70. The disclosure for this sale can be found here. Company insiders own 4.35% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Delpha Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at $102,000. Point72 Asia Hong Kong Ltd lifted its holdings in shares of Alexion Pharmaceuticals by 3,156.7% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 947 shares during the period. CNB Bank bought a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at $150,000. Lucia Wealth Services LLC bought a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at $191,000. Finally, Financial Gravity Wealth Inc. bought a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at $211,000. 92.22% of the stock is currently owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.